Bringing cancer serological diagnosis to a new level: Focusing on HER2, protein ectodomain shedding and neoepitope technology

Future Oncology

Volumn 9, Issue 1, 2013, Pages 35-44

  Wang, Jianxia ^a   Willumsen, Nicholas ^b   Zheng, Qinlong ^a   Xue, Ying ^a   Karsdal, Morten A ^b   Bay Jensen, Anne C ^b  

^a Nordic Bioscience A/S   (China)

^b NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

breast cancer; ECD; ectodomain; extracellular domain; HER2; neoepitope; protein modification; PTMs; shedding

Indexed keywords

ADAM PROTEIN; BIOLOGICAL MARKER; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GEFITINIB; MATRIX METALLOPROTEINASE; MEMBRANE PROTEIN; NEOEPITOPE; PROTEIN ECTODOMAIN; PROTEIN VARIANT; PROTEINASE ACTIVATED RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; VEMURAFENIB;

BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FOOD AND DRUG ADMINISTRATION; GENE OVEREXPRESSION; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PROCESSING; REVIEW; SERODIAGNOSIS; SEROLOGY; TREATMENT RESPONSE;

HUMANS; NEOPLASMS; PROTEOLYSIS; RECEPTOR, ERBB-2; RNA SPLICING; TUMOR MARKERS, BIOLOGICAL;

EID: 84871420626     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.161     Document Type: Review

References (75)

1. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5(11), 845-856 (2005). (Pubitemid 41746029)
2. Rhea JM, Molinaro RJ. Cancer biomarkers: Surviving the journey from bench to bedside. MLO Med. Lab. Obs. 43(3), 10-12, 16, 18; quiz 20, 22 (2011).
3. Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomark. Insights 1, 1-48 (2007).
4. Bertos NR, Park M. Breast cancer Y one term, many entities? J. Clin. Invest. 121(10), 3789-3796 (2011).
5. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14(4), 320-368 (2009).
6. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
7. Parker JL, Lushina N, Bal PS, Petrella T, Dent R, Lopes G. Impact of biomarkers on clinical trial risk in breast cancer. Breast Cancer Res. Treat. 136(1), 179-185 (2012).
8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177-182 (1987). (Pubitemid 17231334)
9. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905), 707-712 (1989). (Pubitemid 19147683)
10. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. The effect of HER-2/ neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15(5), 537-547 (1997). (Pubitemid 27384731)
11. Shih C, Padhy LC, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290(5803), 261-264 (1981). (Pubitemid 11149660)
12. Sundaresan S, Roberts PE, King KL, Sliwkowski MX, Mather JP. Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression. Endocrinology 139(12), 4756-4764 (1998). (Pubitemid 28533420)
13. Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 57(6), 1199-1205 (1997). (Pubitemid 27138623)
14. Bast RC Jr, Ravdin P, Hayes DF et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 19(6), 1865-1878 (2001). (Pubitemid 32230890)
15. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25(1), 118-145 (2007). (Pubitemid 350003059)
16. Carney WP. Hidden HER-2/neu-positive breast cancer: How to maximize detection. IDrugs. 12(4), 238-242 (2009).
17. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin. Chem. 49(10), 1579-1598 (2003). (Pubitemid 37194212)
18. Carney WP, Leitzel K, Ali S, Neumann R, Lipton A. HER-2/neu diagnostics in breast cancer. Breast Cancer Res. 9(3), 207 (2007).
19. Esteva FJ, Cheli CD, Fritsche H et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res. 7(4), R436-R443 (2005).
20. Lam L, McAndrew N, Yee M, Fu T, Tchou JC, Zhang H. Challenges in the clinical utility of the serum test for HER2 ECD. Biochim. Biophys. Acta 1826(1), 199-208 (2012).
21. Tse C, Gauchez AS, Jacot W, Lamy PJ. HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer. Cancer Treat. Rev. 38(2), 133-142 (2012).
22. Thor AD, Liu S, Edgerton S et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer. J. Clin. Oncol. 18(18), 3230-3239 (2000).
23. Christianson TA, Doherty JK, Lin YJ et al. NH2-terminally truncated HER-2/neu protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res. 58(22), 5123-5129 (1998). (Pubitemid 28521172)
24. Schechter AL, Stern DF, Vaidyanathan L et al. The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312(5994), 513-516 (1984). (Pubitemid 15182278)
25. Hynes NE, Stern DF. The biology of erbB- 2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta 1198(2-3), 165-184 (1994).
26. Sasso M, Bianchi F, Ciravolo V, Tagliabue E, Campiglio M. HER2 splice variants and their relevance in breast cancer. J. Nucleic Acids Invest. 2(e9), 52-58 (2011).
27. Marchini C, Gabrielli F, Iezzi M et al. The human splice variant Delta16HER2 induces rapid tumor onset in a reporter transgenic mouse. PLoS One 6(4), e18727 (2011).
28. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61(12), 4744-4749 (2001). (Pubitemid 32691885)
29. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res. 59(6), 1196-1201 (1999). (Pubitemid 29136246)
30. Liu PC, Liu X, Li Y et al. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol. Ther. 5(6), 657-664 (2006). (Pubitemid 44024721)
31. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2(3), 161-174 (2002). (Pubitemid 37328786)
32. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 98(5), 621-628 (2007). (Pubitemid 46563436)
33. Duffy MJ, Mullooly M, O'Donovan N et al. The ADAMs family of proteases: New biomarkers and therapeutic targets for cancer? Clin. Proteom. 8(1), 9 (2011).
34. McKenzie SJ, Marks PJ, Lam T et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 4(5), 543-548 (1989). (Pubitemid 19139705)
35. Leary AF, Hanna WM, van de Vijver MJ et al. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J. Clin. Oncol. 27(10), 1694-1705 (2009).
36. Leahy DJ. A molecular view of anti-ErbB monoclonal antibody therapy. Cancer Cell 13(4), 291-293 (2008). (Pubitemid 351446199)
37. Ghedini GC, Ciravolo V, Tortoreto M et al. Shed HER2 extracellular domain in HER2- mediated tumor growth and in trastuzumab susceptibility. J. Cell Physiol. 225(1), 256-265 (2010).
38. Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JH. Lapatinib for advanced or metastatic breast cancer. Oncologist 17(4), 536-542 (2012).
39. Gomez HL, Doval DC, Chavez MA et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J. Clin. Oncol. 26(18), 2999-3005 (2008).
40. Vazquez-Martin A, Oliveras-Ferraros C, Cufi S, Del BS, Martin-Castillo B, Menendez JA. Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth. J. Cell Physiol. 226(1), 52-57 (2011).
41. Castiglioni F, Tagliabue E, Campiglio M, Pupa SM, Balsari A, Menard S. Role of exon-16-deleted HER2 in breast carcinomas. Endocr. Relat. Cancer 13(1), 221-232 (2006).
42. Mitra D, Brumlik MJ, Okamgba SU et al. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol. Cancer Ther. 8(8), 2152-2162 (2009).
43. Karsdal MA, Henriksen K, Leeming DJ, Woodworth T, Vassiliadis E, Bay-Jensen AC. Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers Y are they the cause or the consequence of the disease? Clin. Biochem. 43(10-11), 793-804 (2010).
44. Vuolteenaho O, la-Kopsala M, Ruskoaho H. BNP as a biomarker in heart disease. Adv. Clin. Chem. 40, 1-36 (2005). (Pubitemid 43588719)
45. Park MC, Chung SJ, Park YB, Lee SK. Bone and cartilage turnover markers, bone mineral density, and radiographic damage in men with ankylosing spondylitis. Yonsei Med. J. 49(2), 288-294 (2008).
46. Madsen SH, Sondergaard BC, Jensen AC, Karsdal MA. Cartilage formation measured by a novel PIINP assay suggests that IGF-I does not stimulate but maintains cartilage formation ex vivo. Scand. J. Rheumatol. 38, 222-226 (2009).
47. Qvist P, Christiansen C, Karsdal MA, Madsen SH, Sondergaard BC, Bay-Jensen AC. Application of biochemical markers in development of drugs for treatment of osteoarthritis. Biomarkers 15(1), 1-19 (2010).
48. Bay-Jensen AC, Sondergaard BC, Christiansen C, Karsdal MA, Madsen SH, Qvist P. Biochemical markers of joint tissue turnover. Assay Drug Dev. Technol. 8(1), 118-124 (2010).
49. Mason SD, Joyce JA. Proteolytic networks in cancer. Trends Cell Biol. 21(4), 228-237 (2011).
50. Carney WP. Circulating oncoproteins HER2/ neu, EGFR and CAIX (MN) as novel cancer biomarkers. Expert Rev. Mol. Diagn. 7(3), 309-319 (2007). (Pubitemid 46798620)
51. Gerber DE. Targeted therapies: A new generation of cancer treatments. Am. Fam. Physician 77(3), 311-319 (2008). (Pubitemid 351206593)
52. Lafky JM, Baron AT, Cora EM et al. Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole. Cancer Res. 65(8), 3059-3062 (2005). (Pubitemid 40524585)
53. Ebos JM, Bocci G, Man S et al. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol. Cancer Res. 2(6), 315-326 (2004). (Pubitemid 39025294)
54. Perez-Torres M, Valle BL, Maihle NJ, Negron- Vega L, Nieves-Alicea R, Cora EM. Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells. Exp. Cell Res. 314(16), 2907-2918 (2008).
55. Elste AP, Petersen I. Expression of proteinase-activated receptor 1-4 (PAR 1-4) in human cancer. J. Mol. Histol. 41(2-3), 89-99 (2010).
56. Adams MN, Ramachandran R, Yau MK et al. Structure, function and pathophysiology of protease activated receptors. Pharmacol. Ther. 130(3), 248-282 (2011).
57. Arora P, Ricks TK, Trejo J. Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. J. Cell Sci. 120(Pt 6), 921-928 (2007). (Pubitemid 46638507)
58. Craig SE, Brady-Kalnay SM. Cancer cells cut homophilic cell adhesion molecules and run. Cancer Res. 71(2), 303-309 (2011).
59. Najy AJ, Day KC, Day ML. The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J. Biol. Chem. 283(26), 18393-18401 (2008).
60. Suzuki M, Raab G, Moses MA, Fernandez CA, Klagsbrun M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J. Biol. Chem. 272(50), 31730-31737 (1997). (Pubitemid 28013322)
61. Pichon MF, Labroquere M, Rezai K, Lokiec F. Variations of soluble fas and cytokeratin 18-Asp 396 neo-epitope in different cancers during chemotherapy. Anticancer Res. 26(3B), 2387-2392 (2006). (Pubitemid 43980206)
62. Leeming DJ, Bay-Jensen AC, Vassiliadis E, Larsen MR, Henriksen K, Karsdal MA. Post-translational modifications of the extracellular matrix are key events in cancer progression: Opportunities for biochemical marker development. Biomarkers 16(3), 193-205 (2011).
63. Leeming D, He Y, Veidal S et al. A novel marker for assessment of liver matrix remodeling: An enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M).Biomarkers 16(7), 616-628 (2011).
64. Barascuk N, Veidal SS, Larsen L et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin. Biochem. 43(10-11), 899-904 (2010).
65. Veidal SS, Karsdal MA, Nawrocki A et al. Assessment of proteolytic degradation of the basement membrane: A fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis Tissue Rep. 4, 22 (2011).
66. Veidal SS, Karsdal MA, Vassiliadis E et al. MMP mediated degradation of type VI collagen is highly associated with liver fibrosis Y identification and validation of a novel biochemical marker assay. PLoS One 6(9), e24753 (2011).
67. Veidal SS, Vassiliadis E, Bay-Jensen AC, Tougas G, Vainer B, Karsdal MA. Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissue Rep. 3(1), 5 (2010).
68. Leeming DJ, Nielsen MJ, Dai Y et al. Enzyme-linked immunosorbent serum assay specific for the 7S domain of collagen type IV (P4NP 7S): A marker related to the extracellular matrix remodeling during liver fibrogenesis. Hepatol. Res. 42(5), 482-493 (2012).
69. Vassiliadis E, Veidal SS, Simonsen H et al. Immunological detection of the type V collagen propeptide fragment, PVCP-1230, in connective tissue remodeling associated with liver fibrosis. Biomarkers 16(5), 426-433 (2011).
70. Mazouni C, Arun B, Andre F et al. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. Br. J. Cancer 99(1), 68-71 (2008).
71. Nicoloff G, Deliiyski T, Nikolov A. Detection of serum collagen type IV and elastin derived peptides in patients with breast cancer. Diabetologia Croatica 39(3), 83-93 (2010).
72. Narita T, Funahashi H, Satoh Y, Takagi H. Procollagen type III N-peptide and type IV collagen 7S-domain in the sera of breast cancer patients. Surg. Today 23(8), 682-686 (1993). (Pubitemid 23233745)
73. Ohlund D, Lundin C, Ardnor B, Oman M, Naredi P, Sund M. Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer. Br. J. Cancer 101(1), 91-97 (2009).
74. Nystrom H, Naredi P, Hafstrom L, Sund M. Type IV collagen as a tumour marker for colorectal liver metastases. Eur. J. Surg. Oncol. 37(7), 611-617 (2011).
75. Kubo S, Tsukamoto T, Hirohashi K et al. Correlation between preoperative serum concentration of type IV collagen 7s domain and hepatic failure following resection of hepatocellular carcinoma. Ann. Surg. 239(2), 186-193 (2004). (Pubitemid 38176352)